Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Vaccine development for breast cancer represents a significant advancement in cancer immunotherapy, aiming to harness the immune system's capacity to recognize and eliminate malignant cells. Unlike traditional vaccines that prevent infections, therapeutic cancer vaccines are designed to stimulate the immune system to target and destroy cancer cells specifically. Alfa Cytology is dedicated to advancing vaccine development for breast cancer through a comprehensive range of services.
Breast cancer (BC) is a malignant tumor originating from the breast duct epithelium. In 2020, BC has become the most common cancer in the world. Currently, chemotherapy, targeted therapy, and endocrine therapy have formed the cornerstone of non-surgical treatment for BC in clinical practice, and the overall cure rate has also been significantly improved. However, current treatments are not effective for patients with advanced BC. The emergence of tumor vaccine therapy is expected to solve this clinical problem. Tumor vaccine therapy can utilize the specific antigens of cancer cells to activate the immune system for a long time, especially because the body has a long-term immune memory, which can reduce the chance of cancer recurrence.
Fig.1 HELA-Exos activated DCs in situ in the breast cancer patient PBMC-autologous tumor organoid coculture system. (Huang L, et al., 2022)
To help researchers develop the safest, most effective BC vaccines, Alfa Cytology has a comprehensive team of scientific, technical, and regulatory experts dedicated to early-stage vaccine development, providing our customers with the right expertise and solutions. Our services include:
| Services | Description |
|---|---|
| Breast cancer whole tumor cell vaccine | It consists of tumor cells or their cell lysate products and specific tumor antigens. Its advantage is that it eliminates the process of predicting and screening dominant epitopes. Moreover, the whole cell fraction provides a large number of antigens that can induce a broad range of MHC-dependent anti-tumor immune responses. |
| Breast cancer dendritic cell vaccine | By activating the patient's own immune system, tumor antigen peptides are used to induce the body to produce corresponding humoral and cellular immune responses, thereby enhancing the body's anti-cancer ability. |
| Breast cancer protein vaccine | Using intact protein (HER2 intracellular or extracellular domain) as a vaccine can avoid specific HLA restrictions because it contains both HLA class I and II epitopes. Studies have demonstrated that protein vaccines can induce specific immunity. |
| Breast cancer peptide vaccine | Peptide vaccines are easy to synthesize, and bioinformatics and other methods can be used to screen candidate amino acid sequences for MHC class I-restricted peptide epitopes with tumor-associated antigens, and these candidate epitopes can be experimentally screened for antigen-specific immune responses. |
| Breast cancer DNA vaccine | DNA vaccine is to inject a recombinant eukaryotic expression vector encoding a certain protein antigen directly into the body, so that the foreign gene can be expressed in vivo. The antigens produced can activate the body's immune system, thereby inducing specific humoral and cellular immune responses. |
| Breast cancer mRNA vaccine | Compared with traditional cancer vaccines, mRNA vaccines have significant advantages, including effective production of protective immune responses, relatively low side effects, and low acquisition costs. |
Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world conducting BC research. We have extensive experience in vaccine design, engineering, characterization, evaluation, animal models, development and more to assist researchers in selecting the most promising vaccine candidates and guide our customers in developing better vaccines. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.
Reference